TRIM26 is an E3 ubiquitin ligase belonging to the TRIM protein family, characterized by a RING domain that catalyzes ubiquitination reactions 1. Its functions are multifaceted and context-dependent, spanning immune regulation, viral defense, and cancer biology. In viral infection, TRIM26 demonstrates dual roles depending on the pathogen. It inhibits hepatitis B virus replication by promoting ubiquitin-mediated degradation of HBx protein 2, and interferon signaling upregulates TRIM26 expression 2. However, TRIM26 can also suppress antiviral immunity by decreasing IRF3 nuclear localization, promoting HSV-2 infection in vaginal epithelial cells [UniProt]. In cancer, TRIM26 exhibits paradoxical roles. In glioma, TRIM26 catalyzes K63-linked ubiquitination of GPX4, enhancing its stability and suppressing ferroptosis, promoting tumorigenesis 3. In colorectal cancer, TRIM26 promotes growth by ubiquitinating p53 and facilitating its degradation 4. Conversely, in clear cell renal cell carcinoma, TRIM26 acts as a tumor suppressor by destabilizing ETK and inactivating AKT/mTOR signaling 5. In hepatocellular carcinoma, TRIM26 suppresses progression through β-catenin ubiquitination 6. TRIM26 is also recruited by RBM4 to degrade LKB1 in esophageal squamous cell carcinoma, promoting glutamine-dependent survival 7. These findings establish TRIM26 as a critical regulator with therapeutic potential in multiple disease contexts.